Posted by Michael Wonder on 20 Oct 2021
Luminopia announces FDA approval of digital therapeutic that uses TV shows to improve vision in children with lazy eye
20 October 2021 - Luminopia One improves vision in children with amblyopia, the leading cause of vision loss in children, and has been validated through a series of clinical studies, including a prospective, randomised controlled trial.
Luminopia today announced that the U.S. FDA has granted de novo premarket approval for Luminopia One as a prescription therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss in children.
